Characterising infusion/injection-related reactions in patients with rheumatoid arthritis treated with biologic agents
Authors' conclusion
IRRs are common among RA patients receiving bDMARDs, particularly in younger individuals or those with prior leflunomide use.
Study context
- Population
- Patients with rheumatoid arthritis (RA) treated with biologic disease-modifying anti-rheumatic drugs (bDMARDs) in the Korean College of Rheumatology Biologics & Targeted Therapy (KOBIO) Registry
- Participants
- 1,832 patients
- Exposure
- RA patients with vs without infusion/injection-related reactions
- Outcome
- Demographic and clinical factors associated with IRRs
Methodological detailsKOBIO Registry, multivariable logistic regression
- KOBIO Registry
- Multivariable logistic regression
Main finding
As reported in the abstract
- IRR incidence
- 9.7%
- Younger age (mean 49.9 vs. 54.9 years), OR
- OR=1.793, p=0.014
- Secondary Sjögren's syndrome, OR
- OR=2.175, p=0.035
- Prior LEF use, OR
- OR=1.497, p=0.015
- Abatacept vs infliximab, OR
- OR=0.263, p<0.001
- Tocilizumab vs infliximab, OR
- OR=0.419, p<0.001
- Golimumab vs infliximab, OR
- OR=0.345, p=0.006
Observational data: associations, not effects.
Further findings
bDMARD switching after infusion/injection-related reactions (IRRs)
- Use of etanercept, infliximab and adalimumab declined; tocilizumab and JAKi increased
Original publication
Characterising infusion/injection-related reactions in patients with rheumatoid arthritis treated with biologic agents. Clin Exp Rheumatol. Published 13 January 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →